Citing Replimune approval, experts say localized cancer meds could redefine care - NewsBreak
• Replimune received approval for Tudriqev, a medication delivered directly to tumors to treat cancer. • This localized delivery approach is also used by Amgen’s Imlygic to target therapeutics specifically at tumor sites. • These approvals suggest a shift toward localized cancer medications that could redefine standard care by reducing systemic side effects.
newsbreak.com
